182 related articles for article (PubMed ID: 32585080)
81. Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice.
Morovat A; Weerasinghe G; Nesbitt V; Hofer M; Agnew T; Quaghebeur G; Sergeant K; Fratter C; Guha N; Mirzazadeh M; Poulton J
J Clin Med; 2017 Aug; 6(8):. PubMed ID: 28825656
[TBL] [Abstract][Full Text] [Related]
82. Potential Biomarkers of Mitochondrial Dysfunction Associated with COVID-19 Infection.
Turton N; Millichap L; Hargreaves IP
Adv Exp Med Biol; 2023; 1412():211-224. PubMed ID: 37378769
[TBL] [Abstract][Full Text] [Related]
83. Laboratory testing for mitochondrial diseases: biomarkers for diagnosis and follow-up.
Paredes-Fuentes AJ; Oliva C; Urreizti R; Yubero D; Artuch R
Crit Rev Clin Lab Sci; 2023 Jun; 60(4):270-289. PubMed ID: 36694353
[TBL] [Abstract][Full Text] [Related]
84. Serum biomarkers in primary mitochondrial disorders.
Varhaug KN; Hikmat O; Nakkestad HL; Vedeler CA; Bindoff LA
Brain Commun; 2021; 3(1):fcaa222. PubMed ID: 33501425
[TBL] [Abstract][Full Text] [Related]
85. Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial disease.
Lehtonen JM; Auranen M; Darin N; Sofou K; Bindoff L; Hikmat O; Uusimaa J; Vieira P; Tulinius M; Lönnqvist T; de Coo IF; Suomalainen A; Isohanni P
J Inherit Metab Dis; 2021 Mar; 44(2):469-480. PubMed ID: 32857451
[TBL] [Abstract][Full Text] [Related]
86. Expanding and validating the biomarkers for mitochondrial diseases.
Maresca A; Del Dotto V; Romagnoli M; La Morgia C; Di Vito L; Capristo M; Valentino ML; Carelli V;
J Mol Med (Berl); 2020 Oct; 98(10):1467-1478. PubMed ID: 32851462
[TBL] [Abstract][Full Text] [Related]
87. Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity.
Sharma R; Reinstadler B; Engelstad K; Skinner OS; Stackowitz E; Haller RG; Clish CB; Pierce K; Walker MA; Fryer R; Oglesbee D; Mao X; Shungu DC; Khatri A; Hirano M; De Vivo DC; Mootha VK
J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463549
[TBL] [Abstract][Full Text] [Related]
88. Metabolic Messengers: FGF21.
Flippo KH; Potthoff MJ
Nat Metab; 2021 Mar; 3(3):309-317. PubMed ID: 33758421
[TBL] [Abstract][Full Text] [Related]
89. Primary mitochondrial myopathy: Clinical features and outcome measures in 118 cases from Italy.
Montano V; Gruosso F; Carelli V; Comi GP; Filosto M; Lamperti C; Mongini T; Musumeci O; Servidei S; Tonin P; Toscano A; Modenese A; Primiano G; Valentino ML; Bortolani S; Marchet S; Meneri M; Tavilla G; Siciliano G; Mancuso M
Neurol Genet; 2020 Dec; 6(6):e519. PubMed ID: 33209982
[TBL] [Abstract][Full Text] [Related]
90. Distal myopathy due to TCAP variants in four unrelated Chinese patients.
Lv X; Gao F; Dai T; Zhao D; Jiang W; Geng H; Liu F; Lin P; Yan C
Neurogenetics; 2021 Mar; 22(1):1-10. PubMed ID: 32761539
[TBL] [Abstract][Full Text] [Related]
91. GDF15 and Cardiac Cells: Current Concepts and New Insights.
Rochette L; Dogon G; Zeller M; Cottin Y; Vergely C
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445593
[TBL] [Abstract][Full Text] [Related]
92. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease.
Wang D; Day EA; Townsend LK; Djordjevic D; Jørgensen SB; Steinberg GR
Nat Rev Endocrinol; 2021 Oct; 17(10):592-607. PubMed ID: 34381196
[TBL] [Abstract][Full Text] [Related]
93. The energetics of cellular life transitions.
Monzel AS; Levin M; Picard M
Life Metab; 2024 Jun; 3(3):. PubMed ID: 38566850
[TBL] [Abstract][Full Text] [Related]
94. Efficacy and Safety of Ketogenic Diet Treatment in Pediatric Patients with Mitochondrial Disease.
Wesół-Kucharska D; Greczan M; Kaczor M; Ehmke Vel Emczyńska-Seliga E; Hajdacka M; Czekuć-Kryśkiewicz E; Piekutowska-Abramczuk D; Halat-Wolska P; Ciara E; Jaworski M; Jezela-Stanek A; Rokicki D
Nutrients; 2024 Mar; 16(6):. PubMed ID: 38542723
[TBL] [Abstract][Full Text] [Related]
95. Mitochondrial dysfunction affects hepatic immune and metabolic remodeling in patients with hepatitis B virus-related acute-on-chronic liver failure.
Zhang Y; Tian XL; Li JQ; Wu DS; Li Q; Chen B
World J Gastroenterol; 2024 Feb; 30(8):881-900. PubMed ID: 38516248
[TBL] [Abstract][Full Text] [Related]
96. Protein biomarkers GDF15 and FGF21 to differentiate mitochondrial hepatopathies from other pediatric liver diseases.
Van Hove JLK; Friederich MW; Strode DK; Van Hove RA; Miller KR; Sharma R; Shah H; Estrella J; Gabel L; Horslen S; Kohli R; Lovell MA; Miethke AG; Molleston JP; Romero R; Squires JE; Alonso EM; Guthery SL; Kamath BM; Loomes KM; Rosenthal P; Mysore KR; Cavallo LA; Valentino PL; Magee JC; Sundaram SS; Sokol RJ;
Hepatol Commun; 2024 Jan; 8(1):. PubMed ID: 38180987
[TBL] [Abstract][Full Text] [Related]
97. Investigation of FGF21 mRNA levels and relative mitochondrial DNA copy number levels and their relation in nonalcoholic fatty liver disease: a case-control study.
Houshmand M; Zeinali V; Hosseini A; Seifi A; Danaei B; Kamfar S
Front Mol Biosci; 2023; 10():1203019. PubMed ID: 37347041
[No Abstract] [Full Text] [Related]
98. Mitochondrial signal transduction.
Picard M; Shirihai OS
Cell Metab; 2022 Nov; 34(11):1620-1653. PubMed ID: 36323233
[TBL] [Abstract][Full Text] [Related]
99. The fibroblast growth factor 21 concentration in children with mitochondrial disease does not depend on the disease stage, but rather on the disease genotype.
Wesół-Kucharska D; Rokicki D; Greczan M; Kaczor M; Czekuć-Kryśkiewicz E; Piekutowska-Abramczuk D; Halat-Wolska P; Ciara E; Jaworski M; Jezela-Stanek A
Pediatr Endocrinol Diabetes Metab; 2022; 28(2):141-151. PubMed ID: 35620925
[TBL] [Abstract][Full Text] [Related]
100. Circulating FGF21 and GDF15 as Biomarkers for Screening, Diagnosis, and Severity Assessment of Primary Mitochondrial Disorders in Children.
Li Y; Li S; Qiu Y; Zhou M; Chen M; Hu Y; Hong S; Jiang L; Guo Y
Front Pediatr; 2022; 10():851534. PubMed ID: 35498801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
